Back to Research Hub
Cogent Biosciences, Inc.
COGT
$31.98+0.82 (+2.63%)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in…
StreetsValue research for Cogent Biosciences, Inc. (COGT)
Members get the full report for Cogent Biosciences, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.